Rituximab: Clinical Trials

1,274 trials of Rituximab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

612 completed, 181 terminated, 149 recruiting, 133 unknown. 1274 Phase 2, 245 Phase 1, 52 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 21274Completed 612, Terminated 181, Recruiting 149, Unknown 133, Active not recruiting 101, Withdrawn 55, Not yet recruiting 34, Suspended 6, Enrolling by invitation 3
Phase 1245Completed 110, Terminated 40, Recruiting 33, Active not recruiting 21, Unknown 20, Withdrawn 12, Not yet recruiting 7, Enrolling by invitation 1, Suspended 1
Phase 352Completed 28, Recruiting 7, Active not recruiting 5, Unknown 5, Terminated 3, Not yet recruiting 2, Withdrawn 2

Follow Rituximab: new trials by email Literature Review of Rituximab trials Research Report on Rituximab

Trials (filtered) newest first · largest first

All 1,274 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma
Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
Phase 2 / Phase 3RecruitingNational Cancer Institute (NCI)2712027-07-272026-11-17
Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies
C9/CD5CAR/IL-15 NK cells, Rituximab, Fludarabine - Hematological Malignancies
Phase 2Not yet recruitingM.D. Anderson Cancer Center702027-02-282026-08-20
Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Phase 1 / Phase 2RecruitingCity of Hope Medical Center582026-12-212026-10-22
A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)
MK-1045, Zilovertamab vedotin, Rituximab - Lymphoma, Large B-Cell, Diffuse, Diffuse Large B-Cell Lymphoma
Phase 2 / Phase 3Not yet recruitingMerck Sharp & Dohme LLC4702026-12-132026-11-05
Pirtobrutinib With Sonrotoclax and Rituximab for High-Risk Relapsed/Refractory Mantle-Cell Lymphoma Following Covalent BTK-Inhibitor Failure
Pirtobrutinib, Sonrotoclax, Rituximab injection - Mantle Cell Lymphoma (MCL), Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Phase 2Not yet recruitingTianjin Medical University Cancer Institute and Hospital352026-12-082026-11-18
Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis
Therapeutic Plasma Exchange, Rituximab, Intravenous immunoglobulin - Idiopathic Pulmonary Fibrosis
Phase 2Not yet recruitingUniversity of Alabama at Birmingham522026-12-012026-10-20
The CARDIOPROTECT Trial
Dexrazoxane, Dexrazoxane placebo, Doxorubicin - Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity
Phase 2Not yet recruitingBeth Israel Deaconess Medical Center602026-12-012026-11-06
Tafasitamab, Lenalidomide, Rituximab, and Orelabrutinib for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Tafasitamab, Lenalidomide, Rituximab - Diffuse Large B Cell Lymphoma (DLBCL)
Phase 2Not yet recruitingSun Yat-sen University292026-12-012026-11-16
Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma
Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisolone (R-CHOP), Epcoritamab, Dexamethasone - Non-Hodgkin's B-cell Lymphoma, Lymphoma Non-Hodgkin
Phase 2Not yet recruitingCarrie Ho, MD202026-11-152026-10-01
Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO)
Loncastuximab tesirine, Rituximab or rituximab biosimilar - Post-transplant Lymphoproliferative Disorder
Phase 1 / Phase 2RecruitingUniversity of Utah232026-11-052026-11-09
Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
Phase 2RecruitingCity of Hope Medical Center352026-10-232026-10-29
A Phase II Study of TT-01488 Tablets in Combination With Anti-CD20 Monoclonal Antibody Therapy in Patients With Mantle Cell Lymphoma
TT-01488 Tablets, Rituximab, Immunomodulatory Agent - Mantle Cell Lymphoma (MCL)
Phase 2Not yet recruitingTransThera Sciences (Nanjing), Inc.1882026-10-102026-10-02
Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma
Rituximab, Tafasitamab, Biospecimen Collection - Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma
Phase 2RecruitingUniversity of Washington302026-10-092026-10-15
Rituximab vs Placebo for Maintenance in Systemic Sclerosis - Interstitial Lung Disease
Rituximab, Placebo - Systemic Sclerosis in Adults
Phase 2Not yet recruitingAssistance Publique - Hôpitaux de Paris1202026-10-012026-09-18
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
NX-5948, venetoclax, rituximab - B-cell Lymphoma, Chronic Lymphocytic Leukemia
Phase 1 / Phase 2RecruitingNurix Therapeutics, Inc.1502026-09-302026-11-16
Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Adult Burkitt Lymphoma
Phase 2RecruitingAIDS Malignancy Consortium432026-09-162026-11-17
Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLL
Lisaftoclax (APG-2575), Rituximab, Pirtobrutinib - Richter Syndrome
Phase 2Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, China232026-09-012026-09-21
Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)
Birelentinib, Rituximab, Cyclophosphamid - Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 2 / Phase 3Not yet recruitingDizal Pharmaceuticals8802026-09-012026-08-05
A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma
BL-M08D1, Rituximab, Gemcitabine Hydrochloride - Diffuse Large B-Cell Lymphoma
Phase 1 / Phase 2Not yet recruitingSichuan Baili Pharmaceutical Co., Ltd.2042026-09-012026-09-14
The HIt HArd and hiT Early in Multiple Sclerosis Trial
Sequential treatment with rituximab and cladribine - Relapsing-remitting Multiple Sclerosis
Phase 2RecruitingUppsala University602026-09-012026-10-22

Showing 20 of 1274. Sign in to see all of them.

Conditions studied

Lymphoma, Large B-Cell, Diffuse (277)  ·  Lymphoma (274)  ·  Lymphoma, Non-Hodgkin (208)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (183)  ·  Lymphoma, Follicular (183)  ·  Lymphoma, Mantle-Cell (161)  ·  Lymphoma, B-Cell, Marginal Zone (104)  ·  Leukemia (88)  ·  Burkitt Lymphoma (80)  ·  Waldenstrom Macroglobulinemia (75)  ·  Lymphoma, B-Cell (69)  ·  Recurrence (61)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (58)  ·  Hodgkin Disease (42)  ·  Lymphoma, Large-Cell, Immunoblastic (42)

Sponsors

M.D. Anderson Cancer Center (113)  ·  National Cancer Institute (NCI) (57)  ·  Hoffmann-La Roche (33)  ·  Memorial Sloan Kettering Cancer Center (25)  ·  Mayo Clinic (20)  ·  Dana-Farber Cancer Institute (17)  ·  Alliance for Clinical Trials in Oncology (16)  ·  Ruijin Hospital (16)  ·  University of Washington (16)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (15)  ·  Weill Medical College of Cornell University (15)  ·  City of Hope Medical Center (13)  ·  Massachusetts General Hospital (13)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (13)  ·  Northwestern University (13)

Countries

United States (743)  ·  China (152)  ·  France (102)  ·  Italy (92)  ·  United Kingdom (87)  ·  Germany (85)  ·  Spain (74)  ·  Canada (59)  ·  Australia (45)  ·  South Korea (43)  ·  Belgium (42)  ·  Poland (36)  ·  Netherlands (33)  ·  Czechia (30)  ·  Sweden (29)

Top investigators

Elias Jabbour (7)  ·  Craig Moskowitz, MD (6)  ·  Ajay Gopal (5)  ·  Daniel O. Persky, MD (5)  ·  Lode J. Swinnen, MD (5)  ·  Richard Burt, MD (5)  ·  Robert O. Dillman, MD, FACP (5)  ·  Wyndham H Wilson, M.D. (5)  ·  Anil Tulpule, MD (4)  ·  Clive S. Zent, MD (4)

Results publications

PMID 39319495, PMID 41671463, PMID 34515338, PMID 39513526, PMID 40550489, PMID 30125215, PMID 30575311, PMID 32770353, PMID 35622074, PMID 35787017, PMID 16551963, PMID 23470153, PMID 23753028, PMID 23834234, PMID 23861248, PMID 24224624, PMID 24802773, PMID 25568347, PMID 26083430, PMID 26132314, PMID 26373676, PMID 27022122, PMID 27282998, PMID 29054815, PMID 29358183, PMID 31208944, PMID 32705923, PMID 33735476, PMID 34797699, PMID 35882475, PMID 35952327, PMID 38271621, PMID 38551807, PMID 38941593, PMID 40802906, PMID 10387937, PMID 10552938, PMID 10845940, PMID 10997973, PMID 11222360, PMID 11509929, PMID 11981005, PMID 12011123, PMID 12070007, PMID 12353309, PMID 12384926, PMID 12393429, PMID 12488408, PMID 12620412, PMID 12637469

NIH funding

2015 (16), 2023 (13), P30CA015704 (13), U10CA031946 (13), U10CA032102 (13), P30CA015083 (11), 2009 (10), P30CA033572 (10), P30CA006973 (9), P30CA016672 (8), 2014 (7), 2005 (6), 2018 (6), U10CA021115 (6), U10CA180821 (6)